Destiny Pharma 145.75p £87.25m (AIM:DEST) The clinical stage innovative biotechnology company focused on the development of novel medicines to prevent.
19 February 2021 | 13:36pm
StockMarketWire.com - SME finance provider Time Finance has appointed Edward Rimmer as interim chief executive to replace outgoing Ian Smith.
He has been hired to the role and as a director of the company with immediate effect.
Smith is expected to leave the company and step down as a director not later than 26 February 2021 and will work until then with Rimmer to complete an orderly handover of duties and regulatory responsibilities .
Rimmer was previously chief operating officer of Time Finance until April 2020, having joined the company in 2017 as managing director of the newly-established commercial finance division comprising the acquired businesses of Gener8 Finance and Positive Cashflow Finance.